- Antiviral drugs
Cytomegalovirus Infection Treatment Market size is valued at USD 278.65 million in 2022 and is poised to grow at a CAGR of 4.8% from 2023-2029. Cytomegalovirus (CMV) infection is the common herpes virus infection having different symptoms which occurs in all ages of people around the world. Cytomegalovirus (CMV) infection is a communicable and easily prone through the body fluids like urine, saliva, blood, breast milk and semen. The infection may spread fast from urine or saliva from people who are infected with CMV having virus in their bodily fluids. The disease can transmit from pregnant to baby during delivery. Organ transplant and Blood transfusion are the other way for the transmission of the disease. Cytomegalovirus infection treatment market is mainly propelling by the rise in the prevalence of CMV infections, growing awareness about herpes disease, pipeline drugs which are promising by key market players for the treatment of CMV infection. Moreover, rise in the support of government, and development of healthcare infrastructure are anticipated to fuel the growth of CMV infection treatment market. However, recent expiries of patented drugs, generic drugs that are available for the treatment like Ganciclovir & Foscarnet are anticipated to hamper the market growth of cytomegalovirus infection treatment. this report studies global market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, The global Cytomegalovirus Infection Treatment Market report includes human demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition. Moreover, PBI analyzed global Cytomegalovirus Infection Treatment Market to better equip clients with possible investment opportunities across the regions (regional Investment Hot-Spots) and market unmet needs (Product opportunities).
Fastest Growing Market
The cytomegalovirus treatment industry is predicted to increase substantially as the number of cases with CMV retinitis rises. CMV retinitis is a rather uncommon symptom of viral disease in other vulnerable groups. It is the earliest symptom of CMV infection in persons with AIDS. In up to 25% of AIDS patients, cytomegalovirus retinitis occurs. A symptom of CMV retinitis is necrotizing retinitis, which can cause retinal organisation and blindness. CMV retinitis and other cytomegalovirus disease symptoms in HIV-1 patients are opportunistic infections that happen when CD4+ cell counts are extremely low. High-value-added active antiretroviral therapy will drive the market for CMV treatment. The global cytomegalovirus treatment market is being driven by the increased demand for CMV therapy due to the rising prevalence of cytomegalovirus retinitis in AIDS patients.
As of 2022, with a market value of USD 278.65 million, it suggests that there is a significant market for CMV treatment, and this market may continue to grow over the next five years.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.